Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 100.0% |
| 2020 | -575.29 Thousand USD | -166.38% |
| 2019 | 866.67 Thousand USD | 299.29% |
| 2018 | -434.88 Thousand USD | 77.04% |
| 2017 | -1.89 Million USD | 35.09% |
| 2016 | -2.91 Million USD | 21.08% |
| 2015 | -3.69 Million USD | 32.84% |
| 2014 | -5.5 Million USD | 38.24% |
| 2013 | -8.91 Million USD | -7.1% |
| 2012 | -8.32 Million USD | -16.75% |
| 2011 | -7.12 Million USD | -50.52% |
| 2010 | -4.73 Million USD | 59.45% |
| 2009 | -11.68 Million USD | 52.51% |
| 2008 | -24.59 Million USD | 2.86% |
| 2007 | -25.32 Million USD | -36.19% |
| 2006 | -18.59 Million USD | -241.68% |
| 2005 | -5.44 Million USD | -1474.58% |
| 2004 | -345.59 Thousand USD | 20.23% |
| 2003 | -433.26 Thousand USD | -108.76% |
| 2002 | 4.94 Million USD | 632.93% |
| 2001 | -928.27 Thousand USD | 97.83% |
| 2000 | -42.81 Million USD | -292.25% |
| 1999 | -10.91 Million USD | 16.06% |
| 1998 | -13 Million USD | -91.43% |
| 1997 | -6.79 Million USD | 18.36% |
| 1996 | -8.32 Million USD | -173.51% |
| 1995 | -3.04 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 100.0% |
| 2020 Q1 | -165.69 Thousand USD | -111.43% |
| 2020 FY | -575.29 Thousand USD | -166.38% |
| 2020 Q3 | -373.83 Thousand USD | -185.78% |
| 2020 Q4 | -455.63 Thousand USD | -21.88% |
| 2020 Q2 | 435.78 Thousand USD | 363.01% |
| 2019 FY | 866.67 Thousand USD | 299.29% |
| 2019 Q1 | -226.36 Thousand USD | 0.0% |
| 2019 Q2 | -226.36 Thousand USD | 0.0% |
| 2019 Q3 | -130.66 Thousand USD | 42.28% |
| 2019 Q4 | 1.45 Million USD | 1209.75% |
| 2018 FY | -434.88 Thousand USD | 77.04% |
| 2017 Q1 | -580.12 Thousand USD | 32.16% |
| 2017 FY | -1.89 Million USD | 35.09% |
| 2016 Q3 | -1.02 Million USD | -66.88% |
| 2016 Q1 | -426.57 Thousand USD | 6.57% |
| 2016 FY | -2.91 Million USD | 21.08% |
| 2016 Q4 | -855.08 Thousand USD | 16.44% |
| 2016 Q2 | -613.22 Thousand USD | -43.75% |
| 2015 Q4 | -456.56 Thousand USD | 61.7% |
| 2015 FY | -3.69 Million USD | 32.84% |
| 2015 Q1 | -609.42 Thousand USD | 62.85% |
| 2015 Q2 | -1.43 Million USD | -136.22% |
| 2015 Q3 | -1.19 Million USD | 17.2% |
| 2014 Q1 | -1.43 Million USD | 47.98% |
| 2014 Q2 | -984.92 Thousand USD | 31.53% |
| 2014 FY | -5.5 Million USD | 38.24% |
| 2014 Q3 | -1.44 Million USD | -46.39% |
| 2014 Q4 | -1.64 Million USD | -13.77% |
| 2013 Q3 | -1.76 Million USD | 16.46% |
| 2013 FY | -8.91 Million USD | -7.1% |
| 2013 Q1 | -2.26 Million USD | -15.49% |
| 2013 Q2 | -2.11 Million USD | 6.4% |
| 2013 Q4 | -2.76 Million USD | -56.32% |
| 2012 Q4 | -1.95 Million USD | -3.38% |
| 2012 FY | -8.32 Million USD | -16.75% |
| 2012 Q3 | -1.89 Million USD | -1.04% |
| 2012 Q2 | -1.87 Million USD | 27.7% |
| 2012 Q1 | -2.59 Million USD | -24.9% |
| 2011 Q2 | -1.76 Million USD | -4.42% |
| 2011 Q1 | -1.68 Million USD | -481.54% |
| 2011 Q4 | -2.07 Million USD | -29.78% |
| 2011 FY | -7.12 Million USD | -50.52% |
| 2011 Q3 | -1.6 Million USD | 9.25% |
| 2010 Q3 | -3.44 Million USD | -399.58% |
| 2010 FY | -4.73 Million USD | 59.45% |
| 2010 Q1 | -1.03 Million USD | -111.16% |
| 2010 Q2 | -690.32 Thousand USD | 33.61% |
| 2010 Q4 | 442.58 Thousand USD | 112.83% |
| 2009 Q2 | -11.14 Million USD | 24.39% |
| 2009 Q3 | 4.88 Million USD | 143.82% |
| 2009 Q4 | 9.31 Million USD | 90.79% |
| 2009 Q1 | -14.73 Million USD | -190.21% |
| 2009 FY | -11.68 Million USD | 52.51% |
| 2008 FY | -24.59 Million USD | 2.86% |
| 2008 Q2 | -6.63 Million USD | 1.48% |
| 2008 Q3 | -6.15 Million USD | 7.28% |
| 2008 Q4 | -5.07 Million USD | 17.45% |
| 2008 Q1 | -6.73 Million USD | 3.97% |
| 2007 Q4 | -7.01 Million USD | -15.57% |
| 2007 Q3 | -6.06 Million USD | 5.21% |
| 2007 Q2 | -6.4 Million USD | -9.61% |
| 2007 FY | -25.32 Million USD | -36.19% |
| 2007 Q1 | -5.83 Million USD | 17.05% |
| 2006 FY | -18.59 Million USD | -241.68% |
| 2006 Q4 | -7.04 Million USD | -29.76% |
| 2006 Q3 | -5.42 Million USD | -51.85% |
| 2006 Q2 | -3.57 Million USD | -39.88% |
| 2006 Q1 | -2.55 Million USD | 0.0% |
| 2005 Q2 | -29.69 Thousand USD | -3.21% |
| 2005 FY | -5.44 Million USD | -1474.58% |
| 2005 Q3 | -75.6 Thousand USD | -154.63% |
| 2005 Q1 | -28.76 Thousand USD | 56.07% |
| 2004 Q3 | -77.57 Thousand USD | 8.16% |
| 2004 Q4 | -65.49 Thousand USD | 15.57% |
| 2004 Q2 | -84.46 Thousand USD | -4.08% |
| 2004 FY | -345.59 Thousand USD | 20.23% |
| 2004 Q1 | -81.15 Thousand USD | 20.76% |
| 2003 FY | -433.26 Thousand USD | -108.76% |
| 2003 Q4 | -102.4 Thousand USD | -11.96% |
| 2003 Q2 | -116.16 Thousand USD | -35.0% |
| 2003 Q1 | -86.05 Thousand USD | 38.35% |
| 2003 Q3 | -91.47 Thousand USD | 21.26% |
| 2002 Q1 | -139.87 Thousand USD | 2.77% |
| 2002 Q2 | -152.81 Thousand USD | -9.25% |
| 2002 Q3 | 5.38 Million USD | 3623.02% |
| 2002 Q4 | -139.58 Thousand USD | -102.59% |
| 2002 FY | 4.94 Million USD | 632.93% |
| 2001 Q1 | -144.61 Thousand USD | 70.63% |
| 2001 Q3 | -156.77 Thousand USD | -16.52% |
| 2001 Q2 | -134.54 Thousand USD | 6.96% |
| 2001 FY | -928.27 Thousand USD | 97.83% |
| 2001 Q4 | -143.86 Thousand USD | 8.23% |
| 2000 Q4 | -492.33 Thousand USD | 97.79% |
| 2000 Q2 | -596.66 Thousand USD | 96.9% |
| 2000 Q1 | -19.21 Million USD | -1175.21% |
| 2000 FY | -42.81 Million USD | -292.25% |
| 2000 Q3 | -22.29 Million USD | -3636.47% |
| 1999 FY | -10.91 Million USD | 16.06% |
| 1999 Q4 | -1.5 Million USD | 0.0% |
| 1998 Q3 | -4.2 Million USD | -23.67% |
| 1998 FY | -13 Million USD | -91.43% |
| 1998 Q1 | -5.1 Million USD | -1600.0% |
| 1998 Q2 | -3.4 Million USD | 33.33% |
| 1997 FY | -6.79 Million USD | 18.36% |
| 1997 Q4 | -300 Thousand USD | 91.41% |
| 1997 Q3 | -3.49 Million USD | -399.06% |
| 1997 Q2 | -700 Thousand USD | 22.22% |
| 1997 Q1 | -900 Thousand USD | 43.75% |
| 1996 FY | -8.32 Million USD | -173.51% |
| 1996 Q1 | -2.1 Million USD | 0.0% |
| 1996 Q2 | -2.1 Million USD | 0.0% |
| 1996 Q3 | -2.02 Million USD | 3.75% |
| 1996 Q4 | -1.6 Million USD | 20.84% |
| 1995 Q4 | -2.1 Million USD | 0.0% |
| 1995 FY | -3.04 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | 100.0% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | 100.0% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | 100.0% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | 100.0% |